BioCentury
ARTICLE | Clinical News

Favipiravir: Completed Phase III enrollment

March 23, 2015 7:00 AM UTC

MediVector completed enrollment of 2,021 adults with uncomplicated influenza in the 2 double-blind, placebo-controlled, international Phase III FAVOR trials evaluating oral favipiravir for 5 days. Pat...